Mineralocorticoid receptor actions in cardiovascular development and disease.


Journal

Essays in biochemistry
ISSN: 1744-1358
Titre abrégé: Essays Biochem
Pays: England
ID NLM: 0043306

Informations de publication

Date de publication:
17 12 2021
Historique:
received: 04 06 2021
revised: 23 07 2021
accepted: 23 07 2021
pubmed: 21 8 2021
medline: 8 4 2022
entrez: 20 8 2021
Statut: ppublish

Résumé

Mineralocorticoid receptors (MRs) are transcriptional regulators that mediate the diverse physiological and pathophysiological actions of corticosteroid hormones across many tissues. In the kidney aldosterone control of sodium/water resorption via DNA-binding actions of the MR is established. MRs also regulate tissues not involved in electrolyte homeostasis such as the heart, adipose tissue, brain, and inflammatory cells where the MRs can respond to both aldosterone and cortisol. The pathology of inappropriate MR activation in non-epithelial tissues are well-described, and steroidal antagonists of the MR have been clinically beneficial in the management of heart failure and blood pressure for decades. However, the role of cortisol-dependent MR activation in the physiological setting is less well defined. Like other steroid hormone receptors, the MR also regulates non-DNA-binding pathways including MAPK pathways and G protein coupled receptors to provide diversity to MR signaling. Whether nonDNA binding pathways are more relevant for MR activation in non-epithelial, versus epithelial, tissues remain unclear. This review will focus on molecular regulation of ligand-dependent MR activation and the physiology and pathophysiology of MR actions in the heart with a focus on the cardiomyocyte and provide a discussion of relevant genomic and non-genomic MR pathways and potential new transcriptional partners for the MR and their relevance for health and disease. Understanding MR actions in the heart will provide new insights into cell-selective mechanisms that underpin the therapeutic benefits of MRAs, and are a critical step towards developing next-generation tissue selective MR modulators with improved safety profiles.

Identifiants

pubmed: 34414409
pii: 229607
doi: 10.1042/EBC20210006
doi:

Substances chimiques

Receptors, G-Protein-Coupled 0
Receptors, Mineralocorticoid 0
Aldosterone 4964P6T9RB

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

901-911

Informations de copyright

© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Morag J Young (MJ)

Baker Heart and Diabetes Institute, Cardiovascular Endocrinology Laboratory, 75 Commercial Rd, Prahran 3181, Australia.

Colin D Clyne (CD)

Hudson Institute of Medical Research, Cancer Drug Discovery, 29-31 Wright St., Clayton 3168, Australia.

Articles similaires

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli et al.
1.00
Humans Multiple Myeloma Receptors, Fibroblast Growth Factor Fibroblast Growth Factors Proto-Oncogene Proteins c-myc
Animals Lung India Sheep Transcriptome

Calcineurin inhibition enhances

Priyanka Das, Alejandro Aballay, Jogender Singh
1.00
Animals Caenorhabditis elegans Longevity Caenorhabditis elegans Proteins Calcineurin
1.00
Animals Mice Immunity, Innate Interneurons Synapses

Classifications MeSH